Nkarta reports Q2 2026 results, continued enrollment in autoimmune NK-cell trials
The company said it expects to present initial data from its Ntrust-1 and Ntrust-2 trials at a medical conference in 2026, with cash it says can fund operations into 2029.
SEC filing